Amyotrophic lateral sclerosis (ALS) is a genetically heterogeneous neurodegenerative
syndrome hallmarked by adult-onset loss of motor neurons. We performed exome sequencing of …

Importance Intravenous edaravone is approved as a disease-modifying drug for patients
with amyotrophic lateral sclerosis (ALS), but evidence for efficacy is limited to short-term …

Objective To determine the diagnostic and prognostic performance of serum neurofilament
light chain (NFL) in amyotrophic lateral sclerosis (ALS). Methods This single-centre, …

Heterozygous missense mutations in the N-terminal motor or coiled-coil domains of the
kinesin family member 5A (KIF5A) gene cause monogenic spastic paraplegia (HSP10) and …

Objective Weight loss has been identified as a negative prognostic factor in amyotrophic
lateral sclerosis, but there is no evidence regarding whether a high‐caloric diet increases …

Background In April 2023, the antisense oligonucleotide tofersen was approved by the US
Food and Drug Administration (FDA) for treatment of SOD1-amyotrophic lateral sclerosis (ALS…

Background and purpose To assess the efficacy and safety of olesoxime, a molecule with
neuroprotective properties, in patients with amyotrophic lateral sclerosis ( ALS ) treated with …

In this review, we summarize the most important recent developments in the treatment of
amyotrophic lateral sclerosis (ALS). In terms of disease-modifying treatment options, several …

Objectives Recent advances in amyotrophic lateral sclerosis (ALS) genetics have revealed
that mutations in any of more than 25 genes can cause ALS, mostly as an autosomal-…

Weight loss is increasingly considered as a negative prognostic marker in amyotrophic
lateral sclerosis (ALS). Despite the critical importance of nutritional issues in ALS, and the …